web analytics
1.9 C
Munich
Sunday, December 4, 2022
type here...

TAG

rgbp

BioPharma

Regen BioPharma Inc (OTCMKTS: RGBP) Breaking Out as Biotech Files Patent on Dendritic Cell Technologies to Augment Efficacy of Survivin mRNA Cancer Immunotherapeutic Vaccine

Boe Rimes -
Regen BioPharma Inc (OTCMKTS: RGBP) is making a powerful reversal rocketing back into penny land on Friday up 46% on $1.6 million in dollar...
BioPharma

Regen BioPharma Inc (OTCMKTS: RGBP) Under Accumulation as Biotech Sleeper Makes Major Reversal Northbound (A look at Intellectual Property / mRNA Vaccine)

Boe Rimes -
Regen BioPharma Inc (OTCMKTS: RGBP) is on the rise in recent trading since reversing off $0.0034 lows last week. RGBP has seen significant decline...
Featured

Regen BioPharma Inc (OTCMKTS: RGBP) Major Reversal Brewing as Biotech Looks to Commercialize its Modified mRNA anti-cancer Vaccine & Accelerate Clinical Development of its...

Boe Rimes -
Regen BioPharma Inc (OTCMKTS: RGBP) has been steadily dropping since topping out at $0.0819 in September of last year. Now it looks like its...
BioPharma

Regen BioPharma Inc (OTCMKTS: RGBP) Northbound as Biotech Grows Valuable Patent Portfolio & Grants 2 Licenses to Oncology Pharma for $1.9 Million

Boe Rimes -
Regen BioPharma Inc (OTCMKTS: RGBP) has been moving steadily northbound in recent trading as speculators move back into the stock and bid it higher....
BioPharma

Regen BioPharma Inc (OTCMKTS: RGBP) Heats Up as Biotech Up Lists & Signs LOI to Acquire Canary Oncoceutics, Inc

Boe Rimes -
Regen BioPharma Inc (OTCMKTS: RGBP) is getting noticed by some heavy hitters after the Company reported earlier this week in its first press release...
Emerging Markets

Regen BioPharma Inc (OTCMKTS: RGBP) Mega Runner as Biotech Moves Towards “Pink Current” & Cancer Vaccine Patent Approved

Boe Rimes -
Regen BioPharma Inc (OTCMKTS: RGBP) is making a powerful run up the charts after the Company's Cancer Vaccine Patent was approved August 17th 2021...
12Page 1 of 2

Latest news

© All rights reserved.

About Us

Popular Category

Editor Picks